Latest Period
Q4 2025
Security Snapshot
CG Oncology, Inc. - Common Stock (CGON) Institutional Ownership
CUSIP: 156944100
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
193
Shares (Excl. Options)
82,634,162
Price
$41.52
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- CGON on Nasdaq
- Shares outstanding
- 76,566,375
- Price per share
- $67.70
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 82,634,162
- Total reported value
- $3,430,444,212
- % of total 13F portfolios
- 0%
- Share change
- +1,329,905
- Value change
- +$57,920,734
- Number of holders
- 193
- Price from insider filings
- $67.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CGON - CG Oncology, Inc. - Common Stock is tracked under CUSIP 156944100.
- 193 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 193 to 129 between Q4 2025 and Q1 2026.
- Reported value moved from $3,430,444,212 to $1,983,974,815.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 193 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 156944100?
CUSIP 156944100 identifies CGON - CG Oncology, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 156944100:
Significant Owners of CG Oncology, Inc. - Common Stock (CGON) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. | 8.4% | $178,215,582 | 6,371,669 | Xiangmin Cui | 31 Dec 2024 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 7.2% | $222,054,738 | 5,512,779 | Wellington Management Group LLP | 30 Sep 2025 | |||
| Longitude Capital Partners IV, LLC | 6% | $121,032,477 | 4,662,268 | Patrick G. Enright | 11 Sep 2025 | |||
| Unique Diamond Investments Ltd | 5.5% | $117,791,208 | 4,211,341 | SONG, Hong Fang | 31 Dec 2024 | |||
| FMR LLC | 5.1% | $100,262,786 | 3,856,261 | FMR LLC | 30 Jun 2025 | |||
| TCG Crossover GP I, LLC | 4.8% | $102,655,662 | 3,670,206 | TCG Crossover GP I, LLC | 31 Mar 2025 | |||
| Seven Fleet Capital Management LP | 2% | $62,145,313 | 1,542,833 | Brian Liu | 06 Oct 2025 | |||
| Seven Fleet Partners LP | 1.9% | $39,333,320 | 1,515,151 | Seven Fleet Partners LP | 11 Sep 2025 |
As of 31 Dec 2025, 193 institutional investors reported holding 82,634,162 shares of CG Oncology, Inc. - Common Stock (CGON). This represents 108% of the company’s total 76,566,375 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of CG Oncology, Inc. - Common Stock (CGON) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 8.5% | 6,539,482 | -0.57% | 0% | $271,519,293 |
| Decheng Capital LLC | 8.3% | 6,371,669 | 0% | 36% | $264,551,697 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.8% | 5,999,790 | +8.8% | 0.04% | $249,111,280 |
| BlackRock, Inc. | 6.3% | 4,843,242 | +5.6% | 0% | $201,091,408 |
| FMR LLC | 5.6% | 4,298,173 | +11% | 0.01% | $178,460,143 |
| TCG Crossover Management, LLC | 4.8% | 3,670,206 | 0% | 5% | $152,386,953 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.5% | 3,443,144 | +117% | 0.02% | $142,961,000 |
| STATE STREET CORP | 3.9% | 2,996,695 | +46% | 0% | $124,422,776 |
| Foresite Capital Management VI LLC | 2.9% | 2,221,474 | 0% | 28% | $92,235,600 |
| RTW INVESTMENTS, LP | 2.6% | 2,012,127 | +18% | 0.84% | $83,543,513 |
| UBS Group AG | 2.5% | 1,923,746 | -9.5% | 0.02% | $79,873,935 |
| BRAIDWELL LP | 2.4% | 1,870,571 | -43% | 2.5% | $77,666,108 |
| ALLIANCEBERNSTEIN L.P. | 2.1% | 1,613,425 | -25% | 0.02% | $66,989,406 |
| FRANKLIN RESOURCES INC | 2% | 1,561,574 | +6.3% | 0.02% | $64,836,553 |
| ORBIMED ADVISORS LLC | 2% | 1,516,550 | -12% | 1.3% | $62,967,156 |
| Seven Fleet Capital Management LP | 2% | 1,515,151 | 0% | 43% | $62,909,069 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,511,533 | +2.6% | 0% | $62,772,944 |
| Avidity Partners Management LP | 1.9% | 1,472,699 | -8% | 18% | $61,146,462 |
| DV Trading LLC | 1.9% | 1,439,393 | 0% | 5.2% | $59,763,597 |
| Pictet Asset Management Holding SA | 1.8% | 1,349,527 | +2.3% | 0.05% | $56,032,361 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,324,603 | -3.1% | 0.01% | $54,997,517 |
| BANK OF AMERICA CORP /DE/ | 1.6% | 1,190,053 | +59% | 0% | $49,411,001 |
| ACORN CAPITAL ADVISORS, LLC | 1.5% | 1,131,501 | 0% | 16% | $46,979,903 |
| Polar Capital Holdings Plc | 1.4% | 1,098,662 | 0% | 0.21% | $45,616,446 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.4% | 1,090,894 | +40% | 0.01% | $45,293,919 |
Institutional Holders of CG Oncology, Inc. - Common Stock (CGON) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 29,345,685 | $1,983,974,815 | -$90,095,216 | $67.68 | 129 |
| 2025 Q4 | 82,634,162 | $3,430,444,212 | +$57,920,734 | $41.52 | 193 |
| 2025 Q3 | 77,648,888 | $3,127,517,509 | +$92,134,469 | $40.28 | 175 |
| 2025 Q2 | 75,914,566 | $1,973,784,426 | +$139,061,983 | $26.00 | 161 |
| 2025 Q1 | 70,762,639 | $1,735,652,621 | +$98,334,837 | $24.49 | 141 |
| 2024 Q4 | 66,057,386 | $1,894,540,823 | +$282,964,154 | $28.68 | 137 |
| 2024 Q3 | 52,183,069 | $1,962,909,867 | +$277,213,171 | $37.73 | 120 |
| 2024 Q2 | 43,274,514 | $1,366,161,770 | +$105,145,067 | $31.57 | 109 |
| 2024 Q1 | 38,771,794 | $1,702,050,758 | +$1,700,470,138 | $43.90 | 96 |